FUSN — Fusion Pharmaceuticals Balance Sheet
0.000.00%
- $1.83bn
- $1.67bn
- $2.07m
Annual balance sheet for Fusion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 65.3 | 222 | 201 | 171 | 234 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.428 | 0.794 | 2.59 | 1.72 | 5.47 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 66.6 | 228 | 212 | 179 | 243 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.27 | 1.97 | 9.45 | 10.3 | 23.9 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 69.4 | 311 | 252 | 219 | 286 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.27 | 11.9 | 12.5 | 15.1 | 16.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 31.3 | 16.2 | 20.8 | 56.8 | 63.4 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 38.1 | 295 | 231 | 162 | 222 |
| Total Liabilities & Shareholders' Equity | 69.4 | 311 | 252 | 219 | 286 |
| Total Common Shares Outstanding |